Last edition
News about "subcutaneous olanzapine injection"
Teva's Olanzapine LAI Shows Long-Term Schizophrenia Efficacy
Teva’s TEV-’749 olanzapine LAI showed high stabilisation rates, low relapse and long-term remission in a phase 3 SOLARIS trial analysis.
Subcutaneous Olanzapine Injection | 22/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members